Meet
Becky Davidson

Associate Principal

Becky Davidson supports clients in market access, product commercialization, and reimbursement strategy.

She applies her experience in economics and public policy to help clients to successfully navigate the complex competitive landscape.

Prior to joining Avalere, Becky was the senior research specialist dedicated to Mylan Pharmaceuticals’ Global Policy department. In addition to providing research support on all aspects of global policy, she assisted company decision-making with SMEs on a broad range of topics including emerging infectious diseases, antimicrobial resistance, drug shortages, and the global supply chain. Previously, Becky worked with a former Federal Trade Commission policy director in private practice, advising consumer and provider associations as well as congressional offices and committees on healthcare antitrust and competition policy.

Becky holds a BS in resource economics from the University of Massachusetts Amherst. She will graduate with an MBA from Georgetown University in 2024.

Authored Content

January 31, 2025 | Insights & Analysis > Coverage and Payment

Impact of J-Code Naming Conventions on 505(b)(2) Drugs
Manufacturers have noted challenges arising from 505(b)(2) code descriptors, prompting CMS to consider proposed updates
April 2, 2024 | Insights & Analysis > Coverage and Payment

Innovation Spurs Growth in Medicare NTAP
Recent growth in the NTAP designation alters dynamics for manufacturers considering pursuing the designation for new technologies.
January 25, 2024 | Insights & Analysis > Federal and State Policy

Assessment of Proposals to Address Drug Shortages
Drug shortages have consequences for a broad range of stakeholders, and policy proposals vary in their ability to address negative impacts.
January 23, 2024 | Insights & Analysis > RWE and Patient-Centered Outcomes

After a Rare Disease Diagnosis, Patient Utilization Rises
Healthcare resource utilization increased for Medicare FFS patients following diagnosis of an ill-defined rare disease.
August 31, 2023 | Insights & Analysis > Value-Based Care

CMS Finalizes Changes to NTAP Payment Designation
The recent FY 2024 IPPS final rule revised NTAP eligibility criteria for certain technologies. Applications for the FY 2025 NTAP cycle are due by October 17, 2023.
August 17, 2023 | Insights & Analysis > Drug Pricing and Affordability

How Will the IRA Impact the Future of Biosimilars?
Multiple Inflation Reduction Act provisions impact biologics and biosimilars, but the net impact and potential consequences will vary across products.
August 8, 2023 | Insights & Analysis > Coverage and Payment

How a New Technology Add-On Payment (NTAP) Works
Additional Medicare payment in the inpatient setting may be available to certain qualifying new technologies, but requires successful navigation of application processes.
April 24, 2023 | Insights & Analysis > Health Equity

Geographic Distribution of Potential Rare Disease Patients’ Residences
Among Medicare Fee-for-Service (FFS) beneficiaries, potential rare disease patients' residences have a median distance of over 200 miles to a relevant clinical trial site.
March 6, 2023 | Insights & Analysis > Regulatory Strategy and FDA Policy

Pre-Approval Information Exchange Aids Manufacturer–Payer Engagement
Clarifications in the PIE Act may shift manufacturer-payer engagement strategy and improve coverage and reimbursement of new drugs and devices.
February 3, 2023 | Insights & Analysis > Regulatory Strategy and FDA Policy

505(b)(2) Changes That Generic Manufacturers Should Know
Regulatory changes to the 505 (b)(2) pathway will impact the go-to-market strategy for follow-on products that are not currently deemed therapeutically equivalent to the reference product.
March 31, 2022 | Insights & Analysis > Vaccines and Public Health

Microarray Patches Could Improve Pandemic Vaccination
The rollout of COVID-19 vaccines highlights the need for continued innovation in how vaccines are delivered.
May 20, 2021 | Insights & Analysis > Federal and State Policy

US Government Continues Investing in Solutions to Combat AMR
As the COVID-19 pandemic draws to a close in the US, another public health concern is once again coming to the fore: antimicrobial resistance (AMR).
February 12, 2021 | Insights & Analysis > Vaccines and Public Health

mAb Utilization for COVID-19 Remains Low, Despite Availability
Since the beginning of the Public Health Emergency (PHE), manufacturers have been developing monoclonal antibodies (mAbs) and other treatment modalities to prevent and treat COVID-19.